A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CARCINOMAS
A study for patients with advanced cancers using study drugs PF-04518600 and PF-05082566
Sponsor: Pfizer
Enrolling: Male and Female Patients
IRB Number: AAAQ8228
U.S. Govt. ID: NCT02315066
Contact: Naiyer Rizvi, MD: 212-305-3997 / nar2144@cumc.columbia.edu
Additional Study Information: The purpose of this research is to learn about the effects of 2 new investigational drugs, PF-04518600 and PF-05082566. PF-04518600 and PF-05082566 are antibodies (a type of protein) which have been shown to stimulate the immune system. Research has shown that an immune response like this can work against tumor cells to slow tumor growth by causing tumor cells to die. PF-04518600 alone and in combination with PF-05082566 are being investigated as possible treatments for research subjects/participants with advanced liver cancer, skin cancer (melanoma), kidney cancer, head and neck cancer, stomach cancer, cervical cancer, gastric cancer, bladder cancer or lung cancer.
This study is closed
Do You Qualify?
Have you been diagnosed with advanced liver, skin, kidney, head/neck, stomach, cervical, gastric, bladder or lung cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Naiyer Rizvi, MD
nar2144@cumc.columbia.edu
212-305-3997